What are the known side effects of Cosentyx after resuming treatment?
[1] According to the Cosentyx webpage on DrugPatentWatch.com, Cosentyx (secukinumab) is a medication used to treat psoriasis, psoriatic arthritis, and ankylosing spondylitis. When patients resume Cosentyx after a period of interruption, they should be aware of the potential side effects that can occur.
Can Cosentyx cause joint pain or muscle weakness in patients resuming treatment?
Patients resuming Cosentyx may experience increased joint pain or muscle weakness, especially if they have a history of these conditions. It is essential for patients to inform their healthcare provider of any previous joint or muscle pain issues before resuming treatment [1].
How does Cosentyx impact the immune system of patients resuming treatment?
Cosentyx can cause changes in immune function, potentially leading to infections, such as bronchitis, sinusitis, or upper respiratory tract infections, in patients resuming treatment. Patients should be aware of the signs and symptoms of infections, such as fever, cough, or difficulty breathing, and inform their healthcare provider promptly [1].
Can patients resuming Cosentyx experience mental health issues?
Some patients resuming Cosentyx may experience mental health issues, including depression, anxiety, or mood changes. It's essential for patients to report any changes in mood or mental health to their healthcare provider [1].
When resuming Cosentyx, what are the steps patients can take to minimize potential side effects?
To minimize potential side effects when resuming Cosentyx, patients should follow their healthcare provider's guidance, stay hydrated, and avoid excessive sun exposure. It's also crucial to adhere to the prescribed dosage regimen [1].
What should patients do if they experience severe side effects after resuming Cosentyx?
If patients experience severe side effects, such as difficulty breathing, swelling of the face or throat, or a severe allergic reaction, they should seek immediate medical attention. In cases of milder side effects, patients should contact their healthcare provider promptly for guidance [1].
Sources:
[1] Cosentyx (secukinumab) - DrugPatentWatch.com (https://www.drugpatentwatch.com/medication/Cosentyx)